Saturday, November 30, 2013

November Performance

It’s time to review my performance for the month of November and year to date. For the month of November, I generated a gain of +2.25%, which underperformed the S&P 500 with a gain of +2.75%. My performance year to date is +40.45%. The positions that hurt my performance in November were Vertex Pharmaceuticals (Ticker: VRTX), Genzyme CVR (Ticker: GCVRZ) and The Jones Group (Ticker: JNY). The strong performers continued to be Constellation Brands (Ticker: STZ), Apple (Ticker: AAPL), Mastercard (Ticker: MA) and Visa (Ticker: V). I’m still playing Spectrum Communications (Ticker: SPRD) and ViroPharma (Ticker: VPHM) by selling Puts as I see these deals closing fairly soon.

The running monthly returns are as follows:

January -0.3%
February +4.67%
March +5.03%
April +5.13%
May +5.13%
June -0.37%
July +2.3%
August +3.3%
September +6.39%
October +6.92%
November +2.25%

I have my portfolio positioned somewhat conservatively as we head toward the close of the year. The primary reason can be attributed to the lack of special situation plays, which I often aggressively lever up. So I have some cash just waiting for the right opportunity…


At December 02, 2013, Anonymous Investing Sidekick said...

Nice returns. Do you find monitoring your portfolio monthly to be ok? I know I tend to get too short term focussed to try and resist and just do it 6 monthly.

At December 02, 2013, Blogger Money Turtle said...

I've just started this year tracking my returns on a monthly basis and I actually find it helpful. It'll be a nice set of data to have for further analysis down the road.

At December 03, 2013, Anonymous Anonymous said...

U think Lemtrada gets approved ?

At December 15, 2013, Blogger Money Turtle said...

I do think Lemtrada will eventually get approval. The tone from the FDA panel meeting was not positive so my bet is a Complete Response Letter with some additional work without a redo of the trial. Who knows, the FDA may surprise and grant approval. We'll see soon...


Post a Comment

<< Home